One Clinical Research

Nedlands, Western Australia WA 6009

7 studies enrolling now · 17 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Solid Tumor, Advanced Solid Tumors, B Cell Lymphoma, Carcinoma, Renal Cell, Cardiovascular Disease, Cardiovascular Diseases, Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, HR+/HER2- Breast Cancer, Mantle Cell Lymphoma, Melanoma

Studies at this site

• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease — Recruiting now
• A Study of BG-C477 in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) — Recruiting now
• Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors — Recruiting now
• A Study of BGB-11417 in Participants With Myeloid Malignancies — Recruiting now
• A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors — Recruiting now
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors — Recruiting now
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — Completed
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels — Running, not enrolling
• A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors — Completed
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight — Completed
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer — Running, not enrolling
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Running, not enrolling
• Screening Study for Participants With Malignant Tumors — Completed
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies — Completed